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diet containing FFBB reduced IL-6, IFN-γ, IL-4 and IL-10 
concentrations, whereas the combination of galacto-oligo-
saccharides and long-chain fructo-oligosaccharides with 
BB was less potent in this model.
Conclusion These findings show that synbiotic dietary 
supplementation can affect respiratory allergic inflamma-
tion induced by HDM. The combination of FFBB was most 
effective in the prevention of HDM-induced airway inflam-
mation in mice.
Keywords House dust mite · Asthma · Allergy · 
Oligosaccharides · Bifidobacterium breve
Abbreviations
AHR  Airway hyperresponsiveness
BALF  Bronchoalveolar lavage fluid
BB  Bifidobacterium breve M-16V
DC  Dendritic cell
FFBB  Short-chain and long-chain fructo-oligosaccharide 
with Bifidobacterium breve M-16V
FOS  Fructo-oligosaccharide
GFBB  Galacto-oligosaccharide and long-chain fructo-oli-
gosaccharide with Bifidobacterium breve M-16V
GOS  Galacto-oligosaccharide
HDM  House dust mite
i.n  Intranasally
ILC2  Innate lymphoid cell type 2
RL  Lung resistance
Introduction
Allergic asthma is a chronic disease that affects around 
235 million people worldwide. Asthma is not only a health 
problem for developed countries but also for developing 
Abstract 
Purpose The incidence and severity of allergic asthma is 
rising, and novel strategies to prevent or treat this disease 
are needed. This study investigated the effects of different 
mixtures of non-digestible oligosaccharides combined with 
Bifidobacterium breve M-16V (BB) on the development of 
allergic airway inflammation in an animal model for house 
dust mite (HDM)-induced allergic asthma.
Methods BALB/c mice were sensitized intranasally (i.n.) 
with HDM and subsequently challenged (i.n.) with PBS or 
HDM while being fed diets containing different oligosac-
charide mixtures in combination with BB or an isocaloric 
identical control diet. Bronchoalveolar lavage fluid (BALF) 
inflammatory cell influx, chemokine and cytokine concen-
trations in lung homogenates and supernatants of ex vivo 
HDM-restimulated lung cells were analyzed.
Results The HDM-induced influx of eosinophils and 
lymphocytes was reduced by the diet containing the short-
chain and long-chain fructo-oligosaccharides and BB 
(FFBB). In addition to the HDM-induced cell influx, con-
centrations of IL-33, CCL17, CCL22, IL-6, IL-13 and 
IL-5 were increased in supernatants of lung homogenates 
or BALF and IL-4, IFN-γ and IL-10 were increased in res-
timulated lung cell suspensions of HDM-allergic mice. The 
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countries, and the prevalence is still increasing [1]. The dis-
ease is characterized by impaired lung function as well as 
airway inflammation containing high numbers of eosino-
phils [2]. House dust mite (HDM) is one of the well-known 
allergens that can trigger allergic diseases such as asthma 
[3]. The inflammatory response, mainly the recruitment 
of eosinophils to the airway tissue and the production of 
cytokines and chemokines, is initiated by HDM-allergen-
specific Th2 cells [4]. During sensitization, allergens can 
directly trigger or stimulate airway epithelial cells, which 
subsequently release different cytokines (e.g., IL-33) and 
chemokines (e.g., CCL20) [5]. In response to IL-33, group 
2 innate lymphoid cells (ILC2) will proliferate and pro-
duce IL-4, -5 and -13 [6]. In addition, IL-33 also induces 
the maturation of dendritic cells (DC) having Th2-inducing 
polarizing capacities [7]. These specific DCs release Th2-
inducing chemokines such as CCL17 and CCL22. The 
activated DCs take up the HDM allergen and induce the 
development of naïve T cells into antigen-specific Th2 cells 
in the local lymph nodes. Subsequently, these Th2 cells 
migrate back to the lung mucosal tissue. After encounter-
ing DC presenting the antigen in the airways, these effector 
Th2 cells will release IL-4, IL-5 and IL-13 [5], which can 
trigger allergic symptoms and eosinophilic inflammation 
[8]. Novel preventive and/or therapeutic approaches are 
needed to prevent and/or treat asthmatic disorders, while 
current treatment is still not sufficient and has considerable 
side effects. Results from animal and human studies sug-
gest that changes in the intestinal microbiota can contrib-
ute to the development of asthma. Indeed different animal 
studies have shown that the gut microbiota affects systemic 
immune function [9–12]. Since the composition of the 
microbiota is important for a balanced immune response, 
adapting the microbiota using oligosaccharides either or 
not combined with beneficial bacteria may help to protect 
against the development of allergic disease. For example, 
treatment with B. breve M-16V was found to suppress air-
way inflammation and treatment with Lactobacillus rham-
nosus also reduced lung resistance in a murine ovalbumin-
induced asthma model [13]. In addition to the direct use 
of probiotics, also specific non-digestible oligosaccharides 
such as galacto-oligosaccharides (GOS) and short-chain 
and long-chain fructo-oligosaccharides (scFOS and lcFOS, 
respectively) can be administered to support growth and/
or activity of bifidobacteria and lactobacilli [9, 14, 15]. In 
previous studies, we have shown that GOS alone are capa-
ble of suppressing HDM-induced airway hyperresponsive-
ness, airway eosinophilia and Th2-related cytokine and 
chemokine concentrations in the lung [16]. Furthermore, 
the combination of GFBB or FFBB with acidic oligosac-
charides reduced allergic responses in food allergic mice 
and suppressed airway inflammation in a mouse model for 
ovalbumin-induced asthma, respectively [17, 18]. In mice 
affected with food allergy, GFBB was more effective than 
GF or BB alone [17]. When GFBB was used in patients suf-
fering from HDM-induced allergy and asthma, the peak 
expiratory flow was increased and the production of sys-
temic Th2 cytokines (IL-4, IL-5 and IL-13) was reduced. 
However, in this study, no effect on bronchial allergic 
inflammation was demonstrated [19]. GOS are prepared 
from lactose derived from cow’s milk. Fructo-oligosac-
charides, obtained from chicory root, provide a vegetable 
source of prebiotic oligosaccharides and may be used as an 
alternative for GOS in the synbiotic mixture. The aim of 
this study was to investigate the effect of two different syn-
biotic mixtures, GFBB and FFBB, on pulmonary inflamma-
tion, cytokine and chemokine concentrations in lungs and 
BALF of HDM-induced asthmatic mice.
Materials and methods
Mice
Six- to eight-week-old, specific pathogen-free, male 
BALB/c mice (Charles River, The Netherlands) were 
housed under bio-contained sterile conditions using 
HEPA®-filtered isocages® (Tecniplast, Italy). Food and 
water were provided ad libitum. All animal experiments 
were conducted in compliance with the Guidelines of the 
Ethical Committee on the Use of Laboratory Animals of 
the Utrecht University (DEC 2013.II.01.003).
Murine HDM‑induced asthma model
While under isoflurane anesthesia, BALB/c mice were 
intranasally (i.n.) sensitized with 1 µg HDM/40 µL PBS 
(Greer Laboratories, USA) on day 0 and challenged once a 
day for 5 consecutive days (day 7–11) with PBS (phosphate 
buffered saline, control, HDM–PBS) or 10 µg HDM/40 µL 
PBS (HDM–HDM) [20]. Mice were ad libitum fed the 
control diet (Research Diet Services, The Netherlands; 
AIN93G, contr), a diet containing a 1 % w/w 9:1 mixture 
of GOS (Vivinal® GOS syrup with approximately 59 % 
GOS, 21 % lactose, 19 % glucose and 1 % galactose on 
dry matter (dry matter of 75 %); FrieslandCampina Domo, 
The Netherlands) and long-chain fructo-oligosaccharides 
(lcFOS, Orafti® HP with approximately ~100 % inulin, 
DP ≥23; Beneo, Belgium; GF) or a 1 % w/w 1:1 mix-
ture of short-chain fructo-oligosaccharides (Orafti® P95, 
with approximately 95 % oligofructose content, DP 2–8; 
Beneo, Belgium) and long-chain fructo-oligosaccharides 
(FF). Carbohydrates in Vivinal® GOS were compensated 
isocalorically in the control diet by means of exchange 
against cellulose (for GOS), lactose (for lactose) and dex-
trose (for glucose). In case of the fructo-oligosaccharides, 
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carbohydrates were compensated isocalorically in the con-
trol diet by means of exchange against cellulose (for FOS). 
Both GF and FF diets contained 2×10E9 colony-forming 
units/g (2 % w/w) Bifidobacterium breve M-16V (BB) 
(Morinaga milk Industry, Japan). The GFBB and FFBB 
diets were given 2 weeks prior to sensitization and were 
continuously provided throughout the entire experimental 
period. Mice were killed on day 14 (see treatment schedule 
in Fig. 1a).
Airway responsiveness measurement
Mice were anaesthetized with a mixture of ketamine 
(Vetoquinol S.A., France; 125 mg/kg) and medetomidine 
(Pfizer, The Netherlands; 0.4 mg/kg), intraperitoneally 
(i.p.). EMKA invasive measurement of dynamic resistance 
(EMKA Technologies, France) in response to increasing 
doses of methacholine (acetyl-β-methyl-choline chloride, 
Sigma-Aldrich, The Netherlands; 0–25 mg/mL, 10 % puff 
for 10 s.) was used to determine the lung function on day 
14 [13]. Basal airway resistance values of each individual 
mouse as measured prior to methacholine exposure were 
deducted from the resistance as measured upon methacho-
line exposure (ΔR; Fig. 1b–c).
Bronchoalveolar lavage
Mice were killed on day 14 using an intraperitoneal over-
dose of pentobarbital (600 mg/kg, Nembutal™, Ceva Santé 
Animale, The Netherlands). Lungs were lavaged with 1 mL 
of pyrogen-free saline (0.9 % NaCl, 37 °C) supplemented 
with protease inhibitor cocktail tablet (Complete Mini, 
Roche Diagnostics, Germany). The supernatant of the first 
mL was used for cytokine and chemokine analyses, fol-
lowed by three lavages with 1 mL saline solution (0.9 % 
NaCl, 37 °C). The BALF cells were centrifuged (400 g, 
5 min), and pellets of the four lavages were pooled; total 
numbers of BALF cells were counted using a Bürker-Türk 
Fig. 1  Treatment protocol of the allergic house dust mite (HDM) 
asthma model and lung resistance measurement. Male BALB/c mice 
were sensitized intranasally (i.n.) with HDM on day 0 and were chal-
lenged i.n. for five consecutive days with HDM or PBS. Mice were 
fed the control diet (AIN93G, contr), a diet containing a 1 % w/w 9:1 
mixture of GOS and long-chain fructo-oligosaccharide (GF) or 1 % 
w/w 1:1 mixture of short-chain fructo-oligosaccharide and long-chain 
fructo-oligosaccharide (FF) both in combination with 2×10E9 col-
ony-forming units/g Bifidobacterium breve M-16V (BB) (2 % w/w). 
The GFBB and FFBB interventions started 2 weeks prior to sensitiza-
tion and continued during the entire experiment. All mice were killed 
on day 14 (a). Basal airway resistance (RL) (b) and ΔRL after base-
line correction in response to increasing doses of methacholine were 
measured on day 14 (c). HDM–PBS: HDM-sensitized and PBS-chal-
lenged mice (white bars), HDM–HDM: HDM-sensitized and HDM-
challenged mice (gray bars), Contr: control diet, GFBB: mixture of 
GOS and long-chain fructo-oligosaccharide with Bifidobacterium 
breve M-16V diet, FFBB: mixture of short-chain fructo-oligosac-
charide and long-chain fructo-oligosaccharide with Bifidobacterium 
breve M-16V diet
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chamber (magnification 100×). Cytospin were stained with 
Diff-Quick (Merz & Dade A.G., Switzerland) for differen-
tial BALF cell counts. Numbers of macrophages, lympho-
cytes, neutrophils and eosinophils were scored using light 
microscopy [21].
Preparation of lung homogenates
Lung samples were homogenized in 1 % Triton X-100 
(Sigma-Aldrich)/PBS containing protease inhibitor (Com-
plete Mini, Roche Diagnostics, Germany) using a Precellys 
24 tissue homogenizer (Bertin Technologies, France). 
Homogenates were centrifuged at 14,000 rpm for 5 min, 
and supernatants were collected. The protein concentration 
of each sample was assayed using the Pierce BCA protein 
assay kit standardized to BSA according to the manufac-
turer’s protocol (Thermo Fisher Scientific, USA). The 
homogenates were diluted to a final concentration of 1 mg 
protein/mL [22, 23].
Ex vivo lung restimulation with house dust mite
Lung cell suspensions were prepared by cutting the lung 
into small pieces and by adding digestion buffer, contain-
ing DNase I and Collagenase A (Roche Diagnostics, Ger-
many), for 30 min. The digestion was stopped using fetal 
calf serum (FCS; Hyclone Laboratories, USA). The lung 
pieces were transferred toward a 70-µm nylon cell strainer 
(BD Biosciences, The Netherlands) and rinsed with 10 mL 
RPMI. Cells were washed and resuspended in RPMI-1640 
culture medium (Lonza, USA) supplemented with 10 % 
heat-inactivated FCS and 0.1 % penicillin–streptomycin 
solution (Sigma-Aldrich). Total number of cells was calcu-
lated using a Beckman Z1 coulter® Particle Counter (Beck-
man, USA). Lung cells (4 × 105 cells/well) were cultured 
in a Greiner bio-one CellSTAR 96-well U-bottom plate 
(Greiner Bio-One B. V., The Netherlands) in medium with 
or without 50 µg/mL HDM (Greer Laboratories, USA). 
The supernatant was harvested after 4 days of culture at 
37 °C in 5 % CO2 and stored at −20 °C until further analy-
sis [13].
Measurement of cytokines
A standard Th1/Th2/Th17 assay (BD Biosciences, The 
Netherlands) was used to determine cytokine concentra-
tions in lung homogenates and supernatants of lung res-
timulation according to the manufacturer’s instructions. 
IL-33, CCL17, CCL20 and CCL22 were measured with a 
DuoSet ELISA (R&D Systems), and IL-13 and IL-5 with a 
Ready-SET-Go!® ELISA (eBioscience, USA). The concen-
trations of these cytokines were expressed as pg/mg protein 
in lung homogenates and pg/mL in BALF and restimula-
tion supernatants.
Statistical analysis
Results are presented as mean ± standard error of mean 
(SEM). Data were statistically analyzed by one-way 
ANOVA and post hoc Bonferroni’s multiple comparisons 
test. P < 0.05 were considered significant. Statistical analy-
ses were conducted using GraphPad Prism software (ver-
sion 6.04).
Results
Dietary intervention with FFBB reduced pulmonary 
eosinophilic inflammation in HDM‑allergic mice
Airway hyperresponsiveness (AHR) to methacholine 
aerosols was measured at baseline; no differences were 
observed between the PBS- and HDM-challenged mice fed 
the different diets (Fig. 1b). In the PBS-challenged mice 
fed the FFBB diet, the baseline airway resistance tended 
to increase compared to PBS mice fed the control diet 
(Fig. 1b); however, methacholine exposure did not signifi-
cantly enhance hyperreactivity in these mice as compared 
to control diet fed mice (Fig. 1c). HDM-challenged mice 
showed a higher AHR response upon methacholine expo-
sure than PBS-challenged mice, but this did not reach sig-
nificance (Fig. 1c). HDM challenge in GFBB- or FFBB-fed 
mice did not increase the AHR response compared to PBS-
challenged mice fed the similar diet (Fig. 1c). Furthermore 
the AHR of HDM-challenged mice fed GFBB or FFBB 
remained below the AHR of HDM-challenged mice fed the 
control diet albeit this did not reach significance (Fig. 1c).
BALF was examined to investigate the inflammatory 
cell influx into the airways of HDM-allergic mice upon 
dietary intervention with control diet or the synbiotic diets 
(Fig. 2a). The total number of inflammatory cells in the 
BALF of HDM–HDM mice fed the control diet was sig-
nificantly increased when compared to HDM–PBS mice 
(Fig. 2a). The HDM challenge induced an increase in the 
number of eosinophils and lymphocytes. The same ten-
dency was shown for macrophages (Fig. 2b–d) compared 
to the PBS-challenged group. Dietary intervention with 
FFBB reduced the total number of inflammatory cells in 
HDM-allergic mice compared to HDM–HDM group fed 
the control diet (Fig. 2a); this reduction was mainly due to 
a decrease in the number of eosinophils and lymphocytes 
(Fig. 2b, c). Dietary intervention with GFBB did not sup-
press the total number of BALF cells (Fig. 2a) or the differ-
entiated cell numbers (Fig. 2b–d). In this group, the number 
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of neutrophils was significantly increased compared to the 
HDM–PBS control group fed the GFBB diet (Fig. 2e).
Effect of synbiotics on inflammatory and Th2‑type 
cytokines and chemokines in lungs of HDM‑allergic 
mice
IL-33, CCL20, CCL17 and CCL22 were significantly 
increased in supernatants of lung homogenates of HDM–
HDM mice fed the control diet compared to the HDM–
PBS control group. Dietary interventions with the different 
synbiotics did not affect these cytokines and chemokines 
(Fig. 3a–d). IL-6 and IL-13 concentrations in the super-
natant of the lung homogenates and IL-5 in BALF of 
HDM–HDM mice fed the control diet showed a signifi-
cant increase compared to the HDM–PBS control group 
(Fig. 4a, c, d). Dietary intervention with FFBB signifi-
cantly decreased the HDM allergy-induced increase in 
IL-6 (Fig. 4a). IL-6 concentrations in lung tissue correlated 
positively with the total number of BALF cells (Fig. 4b, 
r = 0.5011, P = 0.0288). Dietary interventions with the dif-
ferent synbiotics did not affect this HDM-induced increase 
in pulmonary IL-13 (Fig. 4c), but tended to decrease the 
concentrations of IL-5 in the BALF (Fig. 4d). IL-5 concen-
trations in the BALF were positively correlated with the 
number of lymphocytes (Fig. 4e, r = 0.8257, P = 0.0003) 
and the number of eosinophils in the BALF, respectively 
(Fig. 4f, r = 0.7292, P = 0.0028).
Fig. 2  Dietary intervention 
with FFBB reduced pulmonary 
eosinophilic inflammation in the 
lungs of HDM-allergic mice. 
Differentiation of inflammatory 
cell infiltration in the BALF of 
house dust mite-allergic mice. 
HDM–PBS: HDM-sensitized 
and PBS-challenged mice 
(white bars), HDM–HDM: 
HDM-sensitized and HDM-
challenged mice (gray bars), 
Contr: control diet, GFBB: 
mixture of GOS and long-chain 
fructo-oligosaccharide with 
Bifidobacterium breve M-16V 
diet, FFBB: mixture of short-
chain fructo-oligosaccharide 
and long-chain fructo-oligosac-
charide with Bifidobacterium 
breve M-16V diet. Total BALF 
cells (a), absolute number of 
eosinophils (b), lymphocytes 
(c), macrophages (d) and neu-
trophils (e). Results are shown 
as mean ± SEM. Statistical 
significance of differences by 
one-way ANOVA and post hoc 
Bonferroni’s multiple compari-
sons test. *P < 0.05, **P < 0.01, 
***P < 0.001 compared to 
HDM–HDM; $$P < 0.01, 
$$$P < 0.001, $$$$P < 0.0001 
compared to HDM–PBS group 
of corresponding diet, n = 6–9 
mice/group
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Synbiotic diets suppress T cell activity 
in HDM‑allergic mice
To investigate the effects of different synbiotics on aller-
gen-specific cytokine secretion of lung tissue, cell suspen-
sions were ex vivo restimulated with HDM. The concentra-
tions of IL-10, IFNγ and IL-4 were significantly increased 
upon HDM stimulation of lung cells of the HDM–HDM 
mice fed the control diet, whereas HDM–PBS mice showed 
no increase compared to medium stimulation (Fig. 5a–c). 
Dietary intervention with GFBB and FFBB significantly 
decreased the concentrations of IL-10, while FFBB also 
decreased IL-4 and IFNγ (Fig. 5a–c). Although upon HDM 
stimulation IL-17A concentrations were increased in the 
lung cells of HDM–HDM mice fed the control diet, both 
dietary interventions showed no effect (data not shown).
Discussion
This is the first study in which anti-inflammatory effects 
of different oligosaccharide mixtures (e.g., GF or FF) in 
combination with Bifidobacterium breve M-16V (BB) (syn-
biotics) were investigated on the development of HDM-
induced allergic inflammation in a murine model appropri-
ate to mimic human allergic asthma. To mimic the human 
features of asthma, murine models for HDM-allergic 
asthma are commonly used, since HDM is one of the most 
common allergens associated with human allergic asthma 
[24, 25]. In this study, the effects of the synbiotic diets on 
AHR remain unclear; by contrast, strong protective effects 
on airway inflammation were observed in HDM-allergic 
mice. Total inflammatory BALF cell numbers were signifi-
cantly increased in HDM–HDM-allergic mice when com-
pared to HDM–PBS control mice. In contrast to GFBB, 
dietary intervention with FFBB significantly decreased the 
total inflammatory cell number. This decrease was mainly 
due to the reduction in the number of eosinophils and lym-
phocytes compared to HDM–HDM mice fed the control 
diet. Although FFBB was not able to reduce epithelial and 
DC-related cytokines (IL-33) and chemokines (CCL20, 
CCL17 and CCL22) known to contribute to allergic sen-
sitization, FFBB decreased the pro-inflammatory cytokine 
IL-6. IL-6 was found to correlate with the number of 
total inflammatory cells in the BALF. Furthermore, FFBB 
reduced Th2-related cytokines (IL-4 and IL-5) and Th1-
related cytokine IFN-γ concentrations in lung homogenates 
or in supernatants of ex vivo restimulated lung cell suspen-
sions. GFBB was less effective but showed a similar pat-
tern with regard to these parameters, and both FFBB and 
the GFBB diet reduced IL-10 concentrations after ex vivo 
restimulation of lung cells with HDM.
The data show that in particular the FFBB diet was capa-
ble of suppressing airway inflammation, whereas it did not 
suppress Th2-driving mediators such as IL-33, CCL17 and 
CCL22. Epithelial cells are known to secrete IL-33 upon 
Fig. 3  IL-33, CCL20, CCL17 
and CCL22 in lungs of HDM-
allergic mice. IL-33 (a), CCL20 
(b), CCL17 (c) and CCL22 (d) 
concentrations were measured 
in supernatant of lung homoge-
nates. HDM–PBS: HDM-
sensitized and PBS-challenged 
mice (white bars), HDM–HDM: 
HDM-sensitized and HDM-
challenged mice (gray bars), 
Contr: control diet, GFBB: 
mixture of GOS and long-chain 
fructo-oligosaccharide with 
Bifidobacterium breve M-16V 
diet, FFBB: mixture of short-
chain fructo-oligosaccharide 
and long-chain fructo-oligosac-
charide with Bifidobacterium 
breve M-16V diet. Results 
are shown as mean ± SEM. 
Statistical significance of differ-
ences by one-way ANOVA and 
post hoc Bonferroni’s multiple 
comparisons test. *P < 0.05, 
**P < 0.01 compared to HDM–
HDM; $P < 0.05, $$$P < 0.001 
compared to corresponding PBS 
group of diet, n = 5 mice/group
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HDM stimulation, which activates DC [26] and is a che-
moattractant for Th2 cells [27, 28]. IL-33 has also been 
shown to be increased in bronchial biopsies of asthmatic 
patients compared to non-asthmatic patients [29]. In the 
present study, a significant increase in IL-33 concentrations 
was observed in lung homogenates obtained from HDM-
allergic mice and no evidence was found that the dietary 
interventions modulated this increase.
Another relevant chemokine that is produced by the epi-
thelium is CCL20 which is responsible for the attraction 
of immature DC to the lung [26, 30]. From human studies, 
it is known that CCL20 levels are increased in asthmatic 
patients compared to healthy controls, which is even more 
pronounced after allergen challenge [31]. In the current 
study, a significant increase in CCL20 in lung homogenates 
of the HDM–HDM mice compared to the HDM–PBS mice 
fed the control diet was found, which remained unaffected 
by the synbiotic diets.
In patients suffering from atopic asthma, it was shown 
that after a challenge with HDM, the concentrations of 
CCL17 were also increased in the BALF [32]. CCR4 and 
its ligand CCL17 are up-regulated in the airways of asth-
matic patients after challenge and contribute to the Th2 
cell recruitment in asthma [32, 33]. However, CCR4 is not 
only a ligand for CCL17, but it also binds CCL22 with an 
even higher affinity [34]. CCR4 is expressed by regulatory 
T cells, mast cells and Th2 cells and is known to play a 
pivotal role in allergic diseases. In bronchial biopsies of 
asthmatic patients, most of the T lymphocytes were CCR4 
positive [35]. In the current study, a significant increase in 
CCL17 and CCL22 was found in lung tissue of the HDM–
HDM mice compared to the HDM–PBS mice fed the con-
trol diet. However, the synbiotic diets did not affect these 
pulmonary concentrations of CCL17 and CCL22. Overall, 
these results indicate that although the FFBB diet effec-
tively reduced lung eosinophilia and lymphocyte influx, the 
Fig. 4  IL-6, IL-13 and IL-5 in 
lungs of HDM-allergic mice. 
IL-6 (a), IL-13 (c) concentra-
tions were measured in super-
natant of lung homogenates. 
IL-5 (d) was measured in the 
BALF. Correlation of IL-6 in 
lung homogenates and the total 
number of BALF cells (b), IL-5 
in the BALF and the number of 
lymphocytes (e) and IL-5 in the 
BALF and the number of eosin-
ophils (f). HDM–PBS: HDM-
sensitized and PBS-challenged 
mice (white bars), HDM–HDM: 
HDM-sensitized and HDM-
challenged mice (gray bars), 
Contr: control diet, GFBB: 
mixture of GOS and long-chain 
fructo-oligosaccharide with Bifi-
dobacterium breve M-16V diet, 
FFBB: mixture of short-chain 
fructo-oligosaccharide and 
long-chain fructo-oligosaccha-
ride with Bifidobacterium breve 
M-16V diet. Results are shown 
as mean ± SEM. Statistical 
significance of differences by 
one-way ANOVA and post hoc 
Bonferroni’s multiple compari-
sons test. *P < 0.05, **P < 0.01, 
****P < 0.0001 compared 
to HDM–HDM; $$P < 0.01, 
$$$P < 0.001 compared to cor-
responding PBS group of diet, 
n = 5–9 mice/group. Correla-
tion was analyzed using Spear-
man’s correlation test
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diet did not suppress release of Th2-polarizing mediators 
by epithelial cells and/or DC.
IL-6 is produced not only by inflammatory cells such as 
DC and macrophages, but also by lung epithelial cells after 
stimulation with an allergen. The murine model for HDM-
induced allergic asthma showed elevated pulmonary IL-6 
concentrations, which is in line with human studies that 
showed elevated IL-6 levels in BALF, sputum and serum 
from asthmatic patients [36, 37]. Dietary intervention with 
FFBB significantly decreased the concentration of IL-6 
in lung homogenates, which correlated with the observed 
decrease in the influx of inflammatory cells. Hence, the 
decrease in IL-6 by the FFBB diet may relate to the protec-
tive effect of this diet on lung inflammatory responses as 
seen in this animal model.
Besides the pro-inflammatory IL-6, IL-13 and IL-5 are 
also investigated. These allergy-driven cytokines were 
secreted by antigen-specific Th2 cells and mast cells as 
well as by ILCs. IL-13 is also capable of triggering eosin-
ophils and macrophages [38], and IL-5 is a Th2 cytokine 
which is essential for the maturation and activation of 
eosinophils [39]. The concentration of IL-13 in lung tissue 
and IL-5 in the BALF was significantly increased in HDM-
allergic mice compared to control mice. This effect corre-
sponds to human studies which showed that IL-13 levels 
were increased in sputum of asthmatic patients [38, 40, 41]. 
Furthermore, IL-5 mRNA levels are increased in bronchial 
biopsies of asthmatic patients compared to healthy controls 
[42]. Since IL-5 is essential for eosinophil maturation and 
eosinophils are important in asthma, animal and human 
studies showed that eosinophilia in blood and BALF can 
be reduced with monoclonal antibodies against IL-5 [39, 
43]. Although FFBB did not reduce the concentration of 
IL-13 in lung homogenates, it showed a strong tendency 
to decrease the concentration of IL-5. Moreover, IL-5 in 
BALF was positively correlated with eosinophil and lym-
phocyte numbers. The reduction in inflammatory cell influx 
by FFBB may be a consequence of mechanisms involving 
the suppression of challenge-induced IL-6 and IL-5 secre-
tion by lung inflammatory cells.
The FFBB diet suppressed lymphocyte influx, and 
indeed ex vivo antigen-specific restimulation of lung cell 
suspensions showed reduced Th1 (IFNγ)- and Th2 (IL-
4)-type cytokine release by lung cells of HDM-challenged 
mice fed the FFBB diet. IFNγ is a Th1 cytokine which is 
found to be increased in BALF and peripheral blood of 
asthmatic patients. In mouse models, IFNγ is increased at 
mRNA levels in the airway epithelium [44]. IL-4 is one of 
the key players in the development of allergic asthma. A 
high IL-4 milieu is necessary for the differentiation of Th2 
cells that in turn can also produce IL-4 upon antigen bind-
ing [26]. In patients with asthma, increased IL-4 protein 
levels were found in BALF and serum [45]. When patients 
with mild asthma were nebulized with IL-4, an elevation 
of eosinophil number in the sputum was observed. In addi-
tion, it was shown that after nebulizing with anti-IL-4 anti-
bodies, eosinophilic inflammation was reduced in mice 
[46]. Since both allergen-induced IFN-γ and IL-4 were 
decreased after restimulation ex vivo with HDM in the 
FFBB group, these results support the hypothesis that the 
influx of inflammatory cells into the lung tissue upon the 
previous in vivo allergen challenge was reduced by the diet.
The FFBB diet may be capable of reducing the allergen-
specific effector response, which can include regulatory 
Fig. 5  Synbiotic diets suppress antigen-specific T cell activation in 
HDM-allergic mice. Lung cell suspensions were ex vivo restimulated 
with HDM for 4 days (37 °C, 5 % CO2). IL-10 (a), IFNγ (b) and 
IL-4 (c) concentrations were measured in the supernatant. HDM–
PBS: HDM-sensitized and PBS-challenged mice (white bars), HDM–
HDM: HDM-sensitized and HDM-challenged mice (gray bars), 
Contr: control diet, GFBB: mixture of GOS and long-chain fructo-
oligosaccharide with Bifidobacterium breve M-16V diet, FFBB: 
mixture of short-chain fructo-oligosaccharide and long-chain fructo-
oligosaccharide with Bifidobacterium breve M-16V diet. Results are 
shown as mean ± SEM. Statistical significance of differences by 
one-way ANOVA and post hoc Bonferroni’s multiple comparisons 
test. *P < 0.05, **P < 0.01, ***P < 0.001 compared to HDM–HDM; 
^^^P < 0.001, ^^^^P < 0.0001 compared to HDM–PBS, n = 6–7 mice/
group
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cytokines such as IL-10. Upon ex vivo HDM stimulation, 
IL-10 was also decreased in FFBB-fed group. Besides, 
FFBB also GFBB reduced IL-10, whereas IFN-γ and IL-4 
were not significantly lowered by GFBB. This may imply 
that GFBB acts via a different mechanism of action in par-
ticular targeting HDM-induced increase in IL-10 or that 
FFBB is more effective in dampening the inflammatory 
cascade.
Hence, the current study shows a protective effect of die-
tary FFBB in HDM-induced airway inflammation in mice 
when provided before and during allergic sensitization and 
challenge. FFBB did not affect IL-33 and CCL20 induc-
tion, which are known to initiate the development and acti-
vation of CCL17- and CCL22-producing Th2-polarizing 
DC contributing to allergic sensitization. However, FFBB 
may have reduced the influx of eosinophils and allergen-
specific T cells by suppressing local secretion of IL-6 and 
IL-5 by inflammatory cells via currently unknown mecha-
nisms (Fig. 6).
Despite the strong effect of the FFBB diet on airway 
inflammation, it remains to be assessed whether FFBB may 
improve the clinical outcome (asthma) since the effects of 
FFBB on the AHR remained unclear in the current study. 
Future studies are needed to further optimize the effectivity 
of FFBB in prevention and/or treatment of HDM-induced 
asthma. This may include and earlier introduction prior to 
sensitization and dose optimization. Furthermore, combining 
FF with other, bifidobacteria or lactobacillus strains may be 
considered. Indeed in other mice studies, positive effects of 
L. rhamnosus have been observed on AHR and lung inflam-
mation [13, 47]. A combination of FF with this or other 
bacteria might have beneficial effects on allergic asthmatic 
features. The mode of action of FFBB in suppressing lym-
phocyte and eosinophil influx hereby dampening the allergic 
Fig. 6  Overview of the effects of the synbiotic diet FFBB. After the 
initial exposure to HDM, CCL20 is secreted by the airway epithe-
lium, which will activate immature DCs. IL-33, also secreted by the 
epithelium, activates the DCs. Both CCL20 and IL-33 concentrations 
in lung homogenate supernatants were not affected by the FFBB diet. 
Activated DCs secrete CCL17 and CCL22, which are chemo-attract-
ants for Th2 cells, and will traffic to the mediastinal lymph nodes to 
differentiate naïve T cells into Th2 cells. The FFBB diet did not affect 
CCL17 and CCL22 release by these DC. In contrast, IL-6, which 
can be secreted by lung epithelial cells or inflammatory cells such as 
DC, was suppressed which correlated with the reduced inflammatory 
cell influx. Mainly lymphocyte and eosinophil influx was lowered by 
the FFBB diet. Among other cells, Th2 cells secrete IL-13, IL-4 and 
IL-5 and Th1 cells secrete IFN-γ. Although IL-13 remained high, the 
FFBB diet reduced IL-4 and IFNγ. Furthermore, FFBB tended to sup-
press IL-5 levels which correlated with the reduced number of lym-
phocytes and eosinophils upon dietary intervention
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asthma pathway is currently unclear. We hypothesize that 
compared to GFBB, FFBB changes the microbiota in a dif-
ferent manner and via these changes differentially affects the 
mucosal and systemic immune response. One of the ways 
by which this may occur is via altering the levels or pat-
terns of short-chain fatty acids (SCFA) produced upon bac-
terial fermentation of the oligosaccharides in the intestine. 
These SCFA become available in the blood stream and have 
anti-inflammatory properties by acting via the GPR41 and 
GPR43 receptors and are known to suppress airway inflam-
mation [48]. Indeed, SCFA have been shown to dampen 
asthmatic responses in HDM-allergic mice fed a high-fiber 
diet by lowering the number of eosinophils and lymphocytes 
and the concentration of Th2-related cytokines [49]. How-
ever, whether this also underlies the mechanism of FFBB 
needs to be further elucidated. The promising results of our 
study suggest the potential clinical application of this inter-
vention, and in future studies the use of FFBB as an adjunct 
therapy for budesonide treatment, a corticosteroid used to 
treat asthma in humans, may be considered as well.
In conclusion, dietary intervention with a synbiotic sup-
plementation can suppress pulmonary inflammation in HDM 
asthmatic mice, although the FFBB showed a more ben-
eficial effect on the management of HDM-induced allergic 
asthma compared to GFBB. The mode of action of FFBB in 
suppressing airway eosinophilia and lymphocyte numbers 
hereby dampening the allergic asthma pathway needs to be 
further elucidated, but the promising results of our study sug-
gest the potential clinical application of this intervention.
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